Analyst
Canaccord
Equibles does not estimate personal net worth.
Kyle Mixon is recorded as Analyst at Canaccord. Kyle Mixon has spoken on 14 earnings calls and 3 other investor events across 10 companies, most recently for Quanterix Corp on August 12, 2026. Those appearances were for Guardant Health, Inc. (GH), Quanterix Corp (QTRX), Seer, Inc. (SEER), 10x Genomics, Inc. (TXG), GeneDx Holdings Corp. (WGS) and 5 other companies. The companies whose calls Kyle Mixon spoke on are classified in the Healthcare sector.
“Pleased to welcome you to this fireside chat with Quanterex. Here with us today, Quanterex offers a highly sensitive platform based on digital ELISA for, you know, I guess a target on neurology and oncology and we'll talk about more today.”
“I cover life science, tools, and diagnostics for Canaccord. Please welcome me to a fireside chat with GeneDx. From the company, we have CFO Kevin Feely. GeneDx offers a range of testing opportunities for rare disease and genetic disorders focused on whole oxygen and whole genome sequencing primarily.”
“I cover life science tools and diagnosis for Canaccord. Please welcome you to a fireside chat with Verisite. Here with us today, Verisite offers a broad range of tests across thyroid cancer, prostate cancer, cancer, and others.”
“I wanted to ask about instrument placement trends first. so in the first quarter i think 40 percent were previous stack customers and 20 percent were from the sip program this quarter both um were at 30 so i think i understand on the stack side but on the sip side does that just mean they're having more um sip…”
“So, Everett, good to see all these actions that you're taking and all the changes and so forth to improve performance.”
Canaccord
Analyst
Transcript header (unverified)
Diagnostics & Research · Healthcare
QTRX
Medical Devices · Healthcare
SEER
Biotechnology · Healthcare
VCYT
Diagnostics & Research · Healthcare
TEM
Health Information Services · Healthcare
ILMN
Diagnostics & Research · Healthcare
QSI
Medical Devices · Healthcare
